Cantor Fitzgerald Estimates TARA FY2025 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Protara Therapeutics in a report released on Monday, March 17th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings per share of ($1.62) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share.

Protara Therapeutics (NASDAQ:TARA) last issued its earnings results on Wednesday, March 12th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.09.

TARA has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $23.00 price target on shares of Protara Therapeutics in a research report on Thursday, March 6th. Lifesci Capital started coverage on Protara Therapeutics in a research report on Tuesday, March 11th. They set an “outperform” rating and a $22.00 price target for the company. Finally, Guggenheim reiterated a “buy” rating and set a $20.00 price target on shares of Protara Therapeutics in a research report on Friday, December 6th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $22.50.

Protara Therapeutics Trading Down 2.0 %

Shares of TARA opened at $4.33 on Wednesday. The company has a market cap of $89.33 million, a PE ratio of -1.54 and a beta of 1.69. The stock has a 50-day moving average price of $4.36 and a 200-day moving average price of $3.53. Protara Therapeutics has a 12-month low of $1.60 and a 12-month high of $10.48.

Hedge Funds Weigh In On Protara Therapeutics

A number of large investors have recently modified their holdings of the company. RA Capital Management L.P. raised its holdings in shares of Protara Therapeutics by 78.9% during the 4th quarter. RA Capital Management L.P. now owns 3,400,000 shares of the company’s stock valued at $17,952,000 after buying an additional 1,500,000 shares in the last quarter. Janus Henderson Group PLC purchased a new position in shares of Protara Therapeutics during the 4th quarter valued at about $11,938,000. Adage Capital Partners GP L.L.C. purchased a new position in shares of Protara Therapeutics during the 4th quarter valued at about $11,880,000. Toronto Dominion Bank purchased a new position in Protara Therapeutics in the 4th quarter worth approximately $11,030,000. Finally, Blackstone Inc. purchased a new position in Protara Therapeutics in the 4th quarter worth approximately $8,870,000. 38.13% of the stock is owned by hedge funds and other institutional investors.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.